{"preliminary_commentary":{"by_channel":{"x_thread":78,"youtube":42,"podcast":40},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04115007\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-11-05T03:03:40.820Z","note":"From 13 authors, 3 of them verified clinicians. Automated from the 40 newest of 160 indexed sources (Oct 2025 – Oct 2026). Each topic is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":40,"text":"Topics in 40 sources so far: early toxicity with metastasis-directed therapy; early efficacy assessments with metastasis-directed therapy.","authors":13,"kind":"topics","verified_clinicians":3},"drugs_tested":null,"indication":"oligometastatic hormone-sensitive prostate cancer","name":"PRESTO","nct_id":"NCT04115007","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=presto-nct04115007. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"Oligo-PRESTO","arms":[{"description":"Standard of care + Stereotactic Body Radiotherapy to oligometastases","label":"Arm A","type":"EXPERIMENTAL"},{"description":"Standard of care","label":"Arm B","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2031-02-28","type":"ESTIMATED"},"conditions":["Oligometastatic Hormone Sensitive Prostate Cancer"],"enrollment":{"count":550,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Stereotactic Body Radiotherapy (SBRT) + Standard of care","otherNames":[],"type":"RADIATION"},{"name":"Standard of care","otherNames":[],"type":"DRUG"}],"last_update":"2025-06-26","lead_sponsor":"UNICANCER","official_title":"Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients - a GETUG-AFU Phase III Randomized Controlled Trial","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-06-23","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Castration-resistant prostate cancer free survival","timeFrame":"From randomization to castration resistance or death from any cause, up to 1 year"}],"references":[{"citation":"Petrelli F, Ghidini A, Ghidini M, Bukovec R, Trevisan F, Turati L, Indini A, Seghezzi S, Lonati V, Moleri G, Tomasello G, Zaniboni A. Better survival of patients with oligo- compared with polymetastatic cancers: a systematic review and meta-analysis of 173 studies. F1000Res. 2021 May 27;10:423. doi: 10.12688/f1000research.52546.4. eCollection 2021.","pmid":"35602670","type":"DERIVED"}],"start_date":{"date":"2020-06-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients","url":"https://clinicaltrials.gov/study/NCT04115007"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/presto-nct04115007"}